Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998211 | 0.88 | KDM4E (0.59) | KDM4ESMN1; SMN2NPSR1ALDH1A1HPGD | |
| SCHEMBL29828929 | 0.82 | CTNNB1 (0.55) | KDM4ESMN1; SMN2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL5391668 | 0.82 | CTNNB1 (0.55) | KDM4ESMN1; SMN2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL7258149 | 0.80 | NPC1 (0.43) | SMN1; SMN2ALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL11695496 | 0.80 | ALDH1A1 (0.55) | KDM4ESMN1; SMN2NPSR1ALDH1A1HPGD | |
| SCHEMBL28568470 | 0.79 | KDM4E (0.50) | KDM4ESMN1; SMN2NPSR1ALDH1A1HPGD | |
| SCHEMBL8569388 | 0.79 | KDM4E (0.54) | KDM4ESMN1; SMN2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL31181394 | 0.78 | ALDH1A1 (0.55) | KDM4ESMN1; SMN2NPSR1ALDH1A1HPGD | |
| SCHEMBL9016652 | 0.78 | SMN1; SMN2 (0.51) | KDM4ESMN1; SMN2NPSR1ALDH1A1HPGD | |
| SCHEMBL209949 | 0.78 | ALDH1A1 (0.53) | KDM4ESMN1; SMN2NPSR1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6041140-A | — | — | None | — | — | JP | disclosed |
| US-20240277851-A1 | siRNA DELIVERY VECTOR | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-08-22 | — | — | US | disclosed |
| WO-2024140431-A1 | COMPOUNDS COMPRISING HETEROARYL RINGS AND COMPOSITIONS AND METHODS THEREOF | IONGEN THERAPEUTICS CO., LTD. (CN) | 2024-07-04 | — | — | WO | disclosed |
| CN-117396227-A | siRNA delivery vectors | 科学与工业研究委员会 | 2024-01-12 | — | — | CN | disclosed |
| WO-2022254405-A1 | siRNA DELIVERY VECTOR | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-12-08 | — | — | WO | disclosed |
| US-20220119376-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3848367-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-07-14 | — | — | EP | disclosed |
| CN-112745291-A | Compound with HMG-CoA reductase inhibition activity, pharmaceutical composition and application | 浙江大学宁波理工学院 | 2021-05-04 | — | — | CN | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20100331217-A1 | SUBSTRATE PREPARATION PROCESS | AFFYMETRIX, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100298171-A1 | APPARATUS FOR POLYMER SYNTHESIS | AFFYMETRIX, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| WO-2008021369-A2 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-0431943-B1 | Spiro(pyran)piperidine derivatives | MERCK & CO INC (US) | 1998-07-15 | — | — | EP | disclosed |
| US-5633247-A | ANTIARRTHYMIA AGENT | MERCK & CO., INC. (US) | 1997-05-27 | — | — | US | disclosed |
| JP-H0641140-A | CHROMONE DERIVATIVE | MEDICINE INST CHINESE ACAD MEDICAL SCIENCE | 1994-02-15 | — | — | JP | disclosed |
| US-5206240-A | Antiarrhythmia agents | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0431943-A2 | Nitrogen-containing spirocycles | MERCK & CO. INC. (US) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119376-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | CRBN, CSNK2A1, CSNK2A2 | KDM4E 2387/4885SMN1; SMN2 2099/4885NPSR1 3649/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | KDM4E 4181/4885SMN1; SMN2 2866/4885NPSR1 3972/4885 |
| US-20240277851-A1 | siRNA DELIVERY VECTOR | ATP5PD, SSBP1, MFN2 | KDM4E 3718/4885SMN1; SMN2 1863/4885NPSR1 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.